Skip to main content

Table 3 Numbers of patients experiencing a grade 3 or higher adverse event up to 28 days after stopping chemotherapy

From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

  Total n = 49 C1750 mg/m2 C1500 mg/m2
n = 19 n = 30
Hand-foot skin reaction (≥grade 2) 14 (28.6) 6 (31.6) 8 (26.7)
Diarrhoea 13 (26.5) 6 (31.6) 7 (23.3)
Nausea and vomiting 9 (18.4) 4 (21.1) 5 (16.7)
Pain – abdomen 4 (8.2) 2 (10.5) 2 (6.7)
Perforation 4 (8.2) 3 (15.8) 1 (3.3)
Obstruction 2 (4.1) 0 (0.0) 2 (6.7)
Sensory neuropathy 5 (10.2) 2 (10.5) 3 (10.0)
Fatigue 4 (8.2) 2 (10.5) 2 (6.7)
Thrombosis/thrombus/embolism 4 (8.2) 2 (10.5) 2 (6.7)
Hypokalemia 4 (8.2) 2 (10.5) 2 (6.7)
Infection – sepsis 3 (6.1) 0 (0.0) 3 (10.0)
Febrile neutropenia 2 (4.1) 1 (5.3) 1 (3.3)
ALT 1 (2.0) 1 (5.3) 0 (0.0)
Hypertension 0 (0.0) 0 (0.0) 0 (0.0)
Acute respiratory distress syndrome 1 (2.0) 0 (0.0) 1 (3.3)
Any grade 3 or higher adverse event 35 (71.4) 14 (73.8) 21 (70.0)
95% confidence interval (56.7, 83.4) (48.8, 90.9) 50.6, 85.3)